21.10.2020 | short review | Ausgabe 4/2020

Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma
- Zeitschrift:
- memo - Magazine of European Medical Oncology > Ausgabe 4/2020
Wichtige Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Summary
Molecular targeted therapies in pancreatic ductal adenocarcinoma (PDAC) lag behind treatment options in other tumor entities. The POLO trial has provided promising preliminary data for targeting gBRCA in PDAC by the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib. This review tries to show further potential approaches to exploit faulty DNA repair mechanisms beyond gBRCA and olaparib.